NDR welcomes applications for our Funding Innovations in Neurodegenerative Diseases (FIND) program for students.
FIND was established to provide financial support to underfunded novel research that brings new ideas to diagnostics or therapeutics to the field of Amyotrophic Lateral Sclerosis (ALS).
For this program, applications should focus on disease mechanisms related to ALS pathology. Projects will be considered that advance the identification of molecular targets for diagnosis or treatment.
Preference will be given for collaborative efforts with research materials developed by NDR, Inc. researcher partners.
Translational medicine is an interdisciplinary branch of the biomedical field supported by three main pillars: benchside, bedside, and community.
Translational medicine combines disciplines, resources, expertise, and techniques to promote enhancements in prevention, diagnosis, and therapies.
Nowhere is there a greater need for the application of translational medicine than toward treating ALS.
ALS patients are frustrated with the lack of treatment options. Identifying appropriate treatments relies on identifying the disease process and stage present in a patient.
Accomplishing these goals will require selection of molecular targets that change over time.
FIND aims to accelerate translational medicine to ALS patients.
The identification of possible molecules that will serve as biomarkers for diagnostics and drugable targets will be funded up to $10,000.
Targeting common underlying pathological mechanisms, specifically neuroinflammation and phosphokinase pathways support our goals.
Any proposal must have clear specific aims and timelines and be translational in nature. Proposals should focus on effort toward research in ALS.
Award recipients should be able to demonstrate significant progress to specific aims within one year. Successful projects will be supported to publish relevant findings.
Projects will be evaluated with special attention to strategy as well as innovation and an out-of-the-box approach to the stated problem. Funded projects will be required to provide quarterly reports on progress.
Continuation of the award is contingent upon meeting the scientific milestones and timely reporting.